Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Centre of Chinese Medicine, Georgia Rea Rehabilitation Centre, Georgia |
---|---|
Information provided by: | Centre of Chinese Medicine, Georgia |
ClinicalTrials.gov Identifier: | NCT00207428 |
The purpose of this study was evaluation the efficacy of antiepileptic drug carbamazepine in the treatment of mild-to-severe bronchial asthma.
Condition | Intervention | Phase |
---|---|---|
Bronchial Asthma |
Drug: Carbamazepine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Randomized, Placebo Controlled, Double Blind Study of Carbamazepine in Treatment of Bronchial Asthma |
Estimated Enrollment: | 65 |
Study Start Date: | August 1999 |
Estimated Study Completion Date: | April 2000 |
Effective therapy of asthma still remains quite serious problem. According current opinion of leading specialists, asthma is an inflammatory disorder. But asthma also is a paroxysmal disorder: many specialists underline paroxysmal clinical picture of asthma. According to some authors, neurogenic inflammation may play important role in asthma mechanism. But migraine and trigeminal neuralgia are also neurogenic inflammatory paroxysmal diseases, and some antiepileptic drugs, like carbamazepine and valproates, are very effective in therapy of these diseases - more than in 80% of cases. If bronchial asthma also is paroxysmal inflammatory disease, we can suppose a possibility that some antiepileptic drugs also may show high efficacy in asthma therapy. Taken in consideration this hypothesis, we performed a double-blind, placebo-controlled 3-month trial for evaluation of carbamazepine efficacy in treatment of patients with mild-to-severe bronchial asthma.
Comparison: Patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Merab Lomia, MD, PhD | "Rea" Rehabilitation Centre |
Study Director: | Manana Tchaia, MD | Centre of Chinese Medicine |
Study ID Numbers: | LP-CZ-0999-0400 |
Study First Received: | September 13, 2005 |
Last Updated: | May 15, 2006 |
ClinicalTrials.gov Identifier: | NCT00207428 History of Changes |
Health Authority: | Georgia: Ministry of Health |
Bronchial asthma Carbamazepine Efficacy |
Tranquilizing Agents Bronchial Diseases Psychotropic Drugs Central Nervous System Depressants Asthma Antimanic Agents Lung Diseases, Obstructive Hypersensitivity Respiratory Tract Diseases |
Carbamazepine Analgesics, Non-Narcotic Lung Diseases Hypersensitivity, Immediate Analgesics Peripheral Nervous System Agents Anticonvulsants Respiratory Hypersensitivity |
Tranquilizing Agents Bronchial Diseases Immune System Diseases Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Asthma Antimanic Agents Pharmacologic Actions Lung Diseases, Obstructive Hypersensitivity Respiratory Tract Diseases |
Carbamazepine Sensory System Agents Analgesics, Non-Narcotic Lung Diseases Therapeutic Uses Hypersensitivity, Immediate Peripheral Nervous System Agents Analgesics Central Nervous System Agents Anticonvulsants Respiratory Hypersensitivity |